METABOLIC & BARIATRIC SURGERY

Vol. 2, Issue 10  |  September 15, 2026

Surgery within multimodal care, the yield and risks of liver biopsy, and what newer obesity treatments still need to prove.

A — Metabolic Surgery Research

Ricardo V. Cohen, Paulina Salminen, Jaime Ponce and Gerhard Prager | International Journal of Obesity, 2026 | 10.1038/s41366-026-02215-y

A perspective by Cohen and colleagues argues that treatment selection should be guided by obesity-related disease burden rather than by a contest between medications and surgery. The authors distinguish elevated risk from established organ dysfunction or functional limitation, then describe how medical, endoscopic, and surgical care can be coordinated around those needs. They also argue that medication-induced weight loss should not erase the baseline disease severity that supported consideration of surgery. This is a proposed care framework, not a new comparative trial.

For bariatric programs, the practical task is to make reassessment routine rather than wait for a referral after every other option has failed. Baseline complications, treatment response, and the patient's ability to sustain therapy belong in that discussion. A patient doing well on medication may reasonably continue it; intolerance, cost, or an incomplete response may prompt a different plan. The authors disclose industry relationships and surgical-society leadership roles, and their economic arguments depend on the assumptions of cited models.

CLINICAL IMPLICATION

Document the disease burden before treatment, revisit the plan in response, and assess changes. A lower BMI on medication should prompt reassessment, not automatic exclusion of surgery from the conversation.

Hector J. Garcia Navas and colleagues | Surgery for Obesity and Related Diseases, 2026 | 10.1016/j.soard.2026.07.009

Garcia Navas and colleagues examined institutional bariatric cases alongside national MBSAQIP data from 2020 through 2023. Across all 471 local biopsies, histology identified steatohepatitis in 31.6% and fibrosis in 20.6%; these percentages combine routine and selective biopsies. The national results cohort contained 660,817 operations, including 23,096 with biopsy. In the propensity-weighted analysis, transfusion occurred at 7.8 versus 6.2 per 1,000 cases, gastrointestinal bleeding at 4.7 versus 3.8, and readmission at 31.5 versus 29.1, each higher with biopsy.

Biopsy can establish liver disease severity when that information will change follow-up, but diagnostic yield alone does not mandate routine sampling. The small absolute differences in safety deserve discussion alongside the value of a tissue diagnosis. This retrospective comparison cannot remove all selection bias, and the national registry lacks biopsy technique, histology, and long-term hepatic outcomes. Programs adopting a biopsy pathway should also define who reviews the pathology and arranges hepatology care.

KEY FINDING

Local biopsy yield was substantial, but the national analysis did not show a uniform reduction in complications with biopsy. Balance the diagnostic benefit against the observed differences in bleeding and readmission.

Ryan Howard, Ahmad Hider, Jesse Chandler and Justin B. Dimick | JAMA Surgery, 2026 | 10.1001/jamasurg.2026.3996

An analysis of public Medicare data found that primary bariatric surgery rates in fee-for-service beneficiaries fell from 47.1 to 16.6 per 100,000 between 2014 and 2024, a 64.8% decline. Howard and colleagues used an interrupted time series with breakpoints in 2020 and 2022. Rates were already declining by 3.2% annually before the pandemic, dropped abruptly in 2020, and declined by 23.1% annually after 2022. The later acceleration coincided with greater GLP-1 use, but the study cannot establish medication substitution as its cause.

A shrinking operative volume should trigger an access review, not an assumption that patients have all found an effective alternative. Programs can examine referral completion and reasons patients leave the surgical pathway while also accounting for successful medical treatment. These aggregate data cannot separate changes in eligibility, comorbidity, or movement into Medicare Advantage. The post-2022 estimate rests on only three annual observations, which limits confidence in its longer-term trajectory.

CLINICAL IMPLICATION

The decline in fee-for-service Medicare surgery predates both COVID-19 and the widespread use of obesity pharmacotherapy. Preserve informed treatment choice while investigating barriers to surgical evaluation.

B — Science of Obesity Metabolism

Ania M. Jastreboff and colleagues | Endocrine Reviews, 2026 | 10.1210/endrev/bnag025

An Endocrine Society scientific statement reviews what newer obesity medicines have taught us and where the evidence remains incomplete. Jastreboff and colleagues examine the biology of defended fat mass, variation in treatment response, and the relationship between weight reduction and health. The statement also addresses body composition, maintenance, and longer-term medication safety. It is a research agenda rather than a treatment guideline or a new trial.

Bariatric teams face many of the same measurement problems when evaluating combined medical and surgical care. Percent total weight loss remains useful, but it does not fully describe function, disease control, or the consequences of losing lean tissue. Follow-up should connect treatment goals to the complications that matter to the individual patient. Comparative research will also need to distinguish trial efficacy from what patients can sustain when tolerability, cost, and continuity of care come into play.

CLINICAL IMPLICATION

Define success in terms of health as well as weight. This statement identifies questions for better trials and follow-up systems; it does not prescribe a new treatment algorithm.

Florence Porterfield, Jennifer Mulligan, Katherine Salim, Olayemi Olubowale and Fatima Cody Stanford | Endocrinology and Metabolism Clinics of North America, 2026 | 10.1016/j.ecl.2026.07.003

Porterfield and colleagues review reproductive considerations for GLP-1 therapies, including the dual GIP/GLP-1 agonist tirzepatide. They identify reduced oral contraceptive exposure during tirzepatide initiation and dose escalation as a practical prescribing concern. Evidence of improved menstrual or metabolic measures does not yet establish better live-birth outcomes. Early-pregnancy observational studies have not shown a clear signal of malformation, but they cannot establish the safety of continued treatment during pregnancy.

Ask about pregnancy plans and contraceptive use when starting treatment and again during dose escalation. For patients using oral contraception with tirzepatide, the review supports backup contraception for four weeks after initiation and after each dose increase. GLP-1 therapies are not recommended during pregnancy, so preconception planning should include an agent-specific discontinuation plan and support for weight and glycemic control. These conversations also belong in postoperative visits when medication is added for recurrent weight gain or diabetes.

CLINICAL IMPLICATION

Do not treat contraceptive counseling as a one-time intake question. Tirzepatide dose increases create another four-week interval in which patients using oral contraception need backup protection.

Novo Nordisk | Company press release, September 7, 2026 | Source ↗

According to Novo Nordisk's September 7 release, STEP Young met its primary BMI-reduction endpoint in 165 children aged 6 to under 12 with obesity. The randomized, double-blind trial compared weekly semaglutide with placebo over 68 weeks, with lifestyle intervention in both groups. The company reported that 40.4% of treated children, compared with none among those receiving placebo, moved below the age- and sex-specific obesity threshold. That figure uses the trial-product estimand, which estimates the effect if all children adhered to treatment, rather than effectiveness regardless of adherence.

These company-reported, non-peer-reviewed findings concern an age group with substantial unmet treatment needs, but are not an approval announcement. The release does not provide the primary endpoint's numerical treatment difference or detailed adverse-event rates. Novo Nordisk reports no new safety concerns, including for growth and puberty, while longer observation remains important. Pediatric teams will need the detailed results planned for ObesityWeek before judging the size and durability of the benefit relative to the treatment burden.

KEY FINDING

The reported 40.4% threshold result is an adherence-based estimate, not a cure rate. Keep it separate from the still-unreported numerical effect on the primary BMI endpoint.

C — Metabolic Innovation and Technology

Jayson Marwaha and colleagues | Obesity Surgery, 2026 | 10.1007/s11695-026-08905-w

A Michigan Bariatric Surgery Collaborative cohort examined robotic adoption across 87,068 operations performed by 121 surgeons at 41 hospitals between 2006 and 2025. Among 106 peer surgeons, 50 adopted robotics. Peers of high-volume index adopters had lower adjusted odds of adopting the technology themselves (odds ratio 0.30; 95% CI, 0.09–0.84). Sensitivity analyses pointed in the same direction, consistent with the authors' hypothesis that concentrated use may limit colleagues' opportunities.

Recruiting a single productive early adopter does not, by itself, create a broad robotic program. Leaders should examine access to operating room time and to supervised cases before attributing slow adoption to a lack of surgeon interest. This observational association does not establish that index surgeons caused lower peer uptake or that wider uptake would improve patient outcomes. A diffusion plan should pair equitable access to training with outcome monitoring, rather than using case growth alone as its measure of success.

CLINICAL IMPLICATION

Technology adoption depends on access as well as enthusiasm. Audit the opportunities available to peer surgeons rather than assuming that an experienced champion will automatically disseminate expertise.

Hector Garcia Navas and colleagues | Surgical Endoscopy, 2026 | 10.1007/s00464-026-13318-y

In a prospective observational pilot, one surgeon used a robotic-integrated AI measurement tool during sleeve gastrectomy in 12 women. Point-to-point and contour measurements at the gastroesophageal junction and incisura were compared with a surgical ruler. Correlations ranged from 0.79 to 0.90, and absolute mean differences were below 0.1 cm. These are preliminary agreement results, not evidence that the tool improves sleeve geometry or postoperative outcomes.

Digital measurement could make operative documentation more consistent, but a small average bias does not guarantee accuracy in every measurement. The same surgeon selected the landmarks after taking the ruler measurement, and the study used a single platform and a standardized gastric configuration. Validation across operators, anatomy, and operating conditions is needed before generalizing its performance. Asensus supplied imaging equipment, and the corresponding author disclosed a previous consulting relationship with the company.

KEY FINDING

The pilot supports feasibility and preliminary agreement with a ruler. It does not demonstrate fewer leaks, less reflux, or better weight loss.

Lucas Ropek | TechCrunch, September 3, 2026 | Source ↗

TechCrunch reports that OpenAI launched Astra with an emphasis on computer use, software work, and cybersecurity. Its September 3 coverage describes company performance claims alongside concerns about how readily the model's reasoning can be monitored. The article draws on the launch press call and discusses the limits of that oversight. It is technology journalism, not a clinical validation study.

For a bariatric service considering browser-based automation, the relevant question is what the system can do without human oversight. Administrative pilots should start with bounded tasks and permissions that match those tasks. Patient communication, orders, and record changes need explicit review controls, with enough logging to reconstruct actions when something goes wrong. Strong general-purpose benchmarks do not establish safety in a clinical workflow.

CLINICAL IMPLICATION

Evaluate an agent's permissions and audit trail as carefully as its task performance. A model release is not evidence that autonomous clinical use is ready.

D — Metabolic Marketplace

Harith Rajagopalan, Fractyl Health CEO | H.C. Wainwright conference presentation transcript, hosted by Investing.com, September 11, 2026 | Transcript ↗

In an investor presentation, Fractyl CEO Harith Rajagopalan described Revita, an endoscopic duodenal mucosal ablation procedure, as a possible maintenance treatment after GLP-1 withdrawal. He reported six-month weight regain of 5.1% with Revita versus 11.6% with sham in the REMAIN-1 midpoint cohort's intention-to-treat analysis. The stronger one-year maintenance claims concerned a complete-ablation subgroup rather than the entire randomized population. These are preliminary company-presented findings, not independently peer-reviewed pivotal results.

Management expects pivotal topline data in early fourth quarter 2026 and a possible De Novo submission later that quarter. Neither that timetable nor the proposed reimbursement route establishes authorization, coverage, or a viable local business model. Bariatric and endoscopy programs should judge the pivotal population, absolute benefit, and safety before planning services around the procedure. The presentation's Revita-treated safety cohort contained only 29 participants, too few to establish the frequency of uncommon harms.

CLINICAL IMPLICATION

Post-medication weight maintenance is the proposed indication, not a demonstrated replacement for ongoing obesity care. Keep pilot subgroup results, pivotal outcomes, and regulatory expectations separate.

In Memoriam

By Philip Schauer, MD  |  Editor-at-Large, MBS Digest

The international bariatric and metabolic surgery community lost an exceptional surgeon, scientist, educator, and colleague with the passing of Tomasz G. Rogula, MD, PhD, FACS, on August 22, 2026, at the age of 58.

Born in Poland, Tomasz received his MD and PhD from Jagiellonian University in Kraków and completed his surgical training there before coming to the United States. I first met Tomasz in 2002 through Michel Gagner, MD, who strongly recommended him to me while Tomasz was completing a postdoctoral fellowship at Mount Sinai in New York. Tomasz subsequently trained with me at the University of Pittsburgh, first as a research fellow and then as a clinical fellow. Even then, his exceptional technical ability, intellectual curiosity, humility, and work ethic were readily apparent.

He later joined me at Cleveland Clinic, where he developed into an outstanding advanced laparoscopic and bariatric surgeon and surgeon-scientist. His academic work addressed important questions in metabolic and bariatric surgery, including long-term diabetes outcomes, sleeve gastrectomy, revisional surgery, staple-line safety, single-incision techniques, and the critical evaluation of robotic Roux-en-Y gastric bypass. He approached innovation with enthusiasm, but also with appropriate scientific skepticism and a commitment to rigorous evaluation.

Perhaps his most enduring legacy is the International Bariatric Club (IBC). The concept arose at Cleveland Clinic in 2008 from discussions about how to extend excellent journal-club education beyond a single institution. Tomasz, together with Haris Khwaja, MD, and later Ariel Ortiz Lagardere, MD, helped transform that idea into a global educational network. Through virtual journal clubs, debates, case discussions, lectures, and broadcasts, IBC connected thousands of surgeons across countries and continents long before virtual medical education became commonplace.

That vision ultimately led to the IBC Oxford World Congress, now one of the most recognized international gatherings in bariatric and metabolic surgery. This year’s meeting, September 15–17, 2026, carries special meaning as colleagues from around the world gather shortly after Tomasz’s passing to celebrate the community he helped build.

Throughout his career in Cleveland, Poland, and most recently at DHR Health in Texas, Tomasz remained a gifted surgeon, prolific academician, generous teacher, and remarkably inclusive colleague. He was quiet, thoughtful, kind, curious, and deeply committed to bringing people together.

Tomasz believed that surgical knowledge should have no borders. His life’s work helped make that belief a reality.

Production Editor John D. Scott MD FACS
[email protected]

Closing the gaps in knowledge...

For educational purposes. Clinical decisions require individualized assessment.